{"filings":[{"id":705756,"accession_number":"0001628280-26-038630","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-05-28T13:01:18+00:00","items":["5.02","5.07"],"status":"ready","headline":"Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.","Robert More appointed Audit Committee Chair; board size reduced from 8 to 7 upon Ramasastry's departure.","At May 26 annual meeting, Class I directors Robert More, Janet Napolitano, and Elliott Sigal elected; Napolitano received 67.2M for, 54.5M withheld.","Advisory vote on named executive officer compensation approved: 108.5M for, 11.9M against, 1.4M abstain.","Ratification of Ernst & Young as independent auditor for FY2026 approved: 137.0M for, 0.15M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94849,"accession_number":"0001628280-26-031273","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.","Cash, cash equivalents, and investments $809.3M at March 31, 2026; plus $315M Astellas upfront and equity in Q2.","Phase 2 SOLSTICE: 77% (24/31) HDV RNA undetectable at Week 72, rising to 88% (21/24) at Week 96.","Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2/3 in Q1 2027.","Completed $172.5M public offering; closed Astellas collaboration for VIR-5500; first patient dosed in Phase 1 expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":-29000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94848,"accession_number":"0001193125-26-151209","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology CMO Mark Eisner to step down effective April 24, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Eisner, EVP and Chief Medical Officer, leaving role on April 24, 2026.","Company has initiated search for a successor; no replacement named yet.","Departure disclosed in Item 5.02 of the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107525,"accession_number":"0001193125-26-091447","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Bio appoints CEO Marianne De Backer to additional role of President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On March 4, 2026, Vir Bio's Board appointed CEO Marianne De Backer to the additional position of President.","No arrangements or understandings exist between Dr. De Backer and any person regarding her appointment as President.","No family relationship between Dr. De Backer and any Vir Bio director or executive officer.","Dr. De Backer has no direct or indirect interest in any transaction requiring Item 404(a) disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107524,"accession_number":"0001193125-26-084367","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.","Underwriters exercised in full the 30-day option to purchase an additional 2,647,058 shares on Feb 26, 2026.","Offering closed on February 27, 2026; net proceeds after discounts and expenses not disclosed.","Goldman Sachs, Leerink Partners, Evercore, and Barclays acted as representatives of the underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107523,"accession_number":"0001193125-26-077416","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.","Net proceeds estimated at $141.1M, or $162.3M if over-allotment fully exercised.","Underwriters include Goldman Sachs, Leerink Partners, Evercore, Barclays; closing expected Feb 27, 2026.","Proceeds for general corporate purposes; shares sold under existing S-3ASR shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107522,"accession_number":"0001628280-26-010740","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.","Eligible for up to $1.37 billion in development, regulatory and sales milestones plus tiered double-digit royalties on ex-U.S. net sales.","Global development costs shared 40% Vir Bio / 60% Astellas; U.S. profits/losses split 50/50 with Vir co-promotion option.","Phase 1 data for VIR-5500 shows dose-dependent anti-tumor activity; oral presentation at ASCO GU 2026 on February 26.","Cash and investments $781.6M as of Dec 31, 2025; net loss for full year 2025 was $438.0 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107521,"accession_number":"0001628280-26-001768","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.","No grade 3+ treatment-related AEs in combo arm; generally mild/moderate and transient.","Cash, cash equivalents & investments ~$781M at Dec 31, 2025; runway extended into Q4 2027 via Norgine deal.","ECLIPSE 1 Phase 3 topline data expected Q4 2026; ECLIPSE 2/3 top-line in Q1 2027.","VIR-5500 Phase 1 data in prostate cancer to be presented at ASCO GU Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123878,"accession_number":"0001628280-25-057394","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.","Vir receives EUR 55M upfront, up to EUR 495M in milestones, plus tiered mid-teen to high-twenties % royalties.","Norgine to cover ~25% of go-forward external costs for ECLIPSE registrational program.","SOLSTICE Phase 2 data: 66% of CHD patients achieved HDV RNA target not detected at 48 weeks; well-tolerated.","Vir expects current cash, equivalents, and investments to extend into Q4 2027 under current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123877,"accession_number":"0001628280-25-049561","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.","Cash and investments $810.7M as of Sept 30, 2025; runway into mid-2027.","ECLIPSE 1 enrollment completed ~2 months early; topline data for all three HDV studies expected Q1 2027.","VIR-5500 first patient dosed in combo with ARPIs in 1L mCRPC; comprehensive data update planned Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":4486000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140547,"accession_number":"0001628280-25-038329","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.","Cash, investments $892.1M, down $127.7M sequentially; runway into mid-2027.","ECLIPSE registrational program for chronic hepatitis Delta fully underway; ECLIPSE 2 and 3 enrolling patients.","First patient dosed in Phase 1 of VIR-5525 (EGFR-targeting PRO-XTEN T-cell engager); three PRO-XTEN Phase 1 studies ongoing.","R&D expenses $97.5M (down from $105.1M) reflecting restructuring savings partially offset by clinical costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":4246000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140546,"accession_number":"0001628280-25-035847","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).","Dosing triggers a $75M milestone payment to Sanofi under the 2024 license agreement, recognized as R&D expense in Q3 2025.","$75M milestone was held as restricted cash and excluded from the $1.02B cash reported as of March 31, 2025.","Dose escalation continues for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA) in heavily pretreated patients, showing early response signals.","VIR-5525 is Vir's third dual-masked TCE in clinical trials; preclinical candidates integrating PRO-XTEN and AI discovery are advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158249,"accession_number":"0001628280-25-028356","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vir Biotechnology stockholders elect directors, approve executive pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jeffrey S. Hatfield and Saira Ramasastry elected as Class III directors each with >93 million votes for.","Advisory vote on executive compensation approved: 100.5 million for, 4.3 million against.","Ernst & Young LLP ratified as independent auditor for FY 2025 (116.3 million for).","All three proposals passed; no material change in governance or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158248,"accession_number":"0001628280-25-024067","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.","No global development partner secured for chronic HBV; Phase 3 will not proceed.","Company to streamline final stages of MARCH Phase 2, focusing on hepatitis delta ECLIPSE Phase 3 and T-cell engager oncology programs.","Cash runway guidance into mid-2027 reaffirmed based on current operating plan.","Safety profile consistent; no new concerns; generally mild/moderate adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158247,"accession_number":"0001628280-25-023175","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.","Initiated Phase 3 ECLIPSE registrational program for chronic hepatitis delta; first patient enrolled March 2025.","Cash and investments ~$1.02B, down $75.6M in Q1; cash runway into mid-2027.","Alnylam opted out of profit-sharing for elebsiran in CHB/CHD; Vir seeking partner for CHB development.","Dose escalation ongoing for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA); Phase 1 for VIR-5525 (EGFR) planned Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":3032000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176626,"accession_number":"0001628280-25-008163","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.","Net loss for Q4 2024 was $104.6 million ($0.76 per share) vs $116.0 million ($0.86 per share) in Q4 2023.","Phase 3 ECLIPSE registrational program in chronic hepatitis delta on track for first patient in first half of 2025.","Initial Phase 1 data for VIR-5818 showed tumor shrinkage in 50% (10/20) of participants at doses ≥400 µg/kg.","Company plans to initiate Phase 1 study of VIR-5525, dual-masked EGFR-targeting T-cell engager, in first half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":74205000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176625,"accession_number":"0001628280-25-003073","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vir Biotechnology CTO to depart Feb 26; Maninder Hora appointed as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ann (Aine) M. Hanly, EVP and Chief Technology Officer, will leave Vir Biotechnology on February 26, 2025.","Maninder Hora, Ph.D. appointed as EVP and Chief Technical Operations Officer, effective February 27, 2025.","Dr. Hora will assume all responsibilities formerly held by Dr. Hanly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176624,"accession_number":"0001193125-25-003214","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.","VIR-5500 (PSMA mCRPC): PSA declines in 100% (12/12) and PSA50 response in 58% (7/12) at first dose ≥120 µg/kg.","Safety: No dose-limiting CRS; max grade 2 CRS; MTD not reached for either TCE; dosing up to 1000 µg/kg.","PRO-XTEN masking technology shows minimal systemic unmasking; half-life 6-10 days enabling Q3W dosing.","Phase 1 trials ongoing; dose escalation continues; company to hold investor call Jan 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193466,"accession_number":"0001628280-24-044563","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.","Closed exclusive worldwide license with Sanofi for three dual-masked T-cell engagers; paid $103.7M upfront.","Workforce reduction of ~25% (140 employees) as part of restructuring; expects ~435 employees by year-end.","Jason O'Byrne appointed as CFO effective Oct 2, 2024; brings 20+ years finance experience.","R&D expenses surged to $195.2M (including $102.8M Sanofi upfront IPR&D); SG&A down to $25.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":61831000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209778,"accession_number":"0001628280-24-039948","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["2.01","5.02","7.01","9.01"],"status":"ready","headline":"Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.","Upfront payment $100M plus $75M escrowed milestone; up to $323M dev/reg milestones, $1.488B sales milestones, and low single to low double-digit tiered royalties.","Jason O'Byrne appointed EVP and CFO effective Oct 2, 2024; base salary $530K, target bonus 45%, sign-on $450K, equity awards of 150K options and 75K RSUs.","Clinical assets: SAR446309 (HER2) in Phase 1, SAR446329 (PSMA) in Phase 1, SAR446368 (EGFR) IND active, Phase 1 start expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209777,"accession_number":"0001628280-24-034143","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.","Strategic restructuring reduces workforce by ~140 employees (25%); phases out flu, COVID-19, and T-cell viral vector programs.","Expects $11–13M in restructuring charges, ~$50M annual workforce cost savings from 2025, and ~$50M program savings through 2025.","Lowers full-year 2024 GAAP operating expense guidance to $580–610M, excluding Sanofi transaction impact.","Signed exclusive worldwide license with Sanofi for clinical-stage T-cell engagers; CMO Mark Eisner appointed June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":59451000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209776,"accession_number":"0001193125-24-191500","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.","Eligible for up to $323M in development/regulatory milestones and up to $1.488B in commercial sales milestones.","License covers SAR446309, SAR446329, and SAR446368 (AMX-525) masked T-cell engagers and protease-cleavable masking platform.","Exclusive worldwide license for oncology and infectious disease, excluding ophthalmology; low single-digit to low double-digit tiered royalties.","Closing contingent on expiration or termination of applicable HSR waiting period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227963,"accession_number":"0001193125-24-168554","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.","Phase 2 SOLSTICE 24-week data expected Q4 2024; preliminary data showed high virologic response.","Company plans ECLIPSE trial to support potential registration, comparing combo to standard of care.","CEO Marianne De Backer says IND clearance underscores potential to transform treatment landscape.","Hepatitis delta affects at least 12 million people globally; considered most severe viral hepatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227962,"accession_number":"0001193125-24-154636","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.","Tobevibart monotherapy: 55% (6/11) combined endpoint at week 24.","No serious adverse events, no ALT flares; majority of AEs Grade 1-2 and transient.","Company to report additional 24-week data for all ~60 participants in Q4 2024.","Data to be presented at EASL Congress on June 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227961,"accession_number":"0001193125-24-149139","cik":1706431,"company_name":"Vir Biotechnology, Inc.","ticker":"VIR","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vir Biotechnology shareholders elect Class II directors, approve advisory compensation, ratify EY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors De Backer, Bischofberger, Farid, Nelsen elected with votes for/withheld: 105.6M/1.1M, 80.0M/26.7M, 106.4M/0.3M, 67.9M/38.8M; broker non-votes 12.3M.","Advisory vote on executive compensation approved: 83.9M for, 22.6M against, 0.2M abstain; broker non-votes 12.3M.","Ratification of Ernst & Young as auditor: 118.1M for, 679,046 against, 168,971 abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1438600000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}